Subscribe

China National Accord Medicines Corporation Ltd. (000028.SZ)

CNY21.09 +0.32 (+1.54%)
CN SHZ Healthcare Medical - Distribution
Address Accord Pharm. Building 518029
Shenzhen, CN
CEO Zhaoxiong Lin
Website szaccord.com.cn
IPO 1993-06-08
ISIN CNE0000009N6

Explore sections of this company profile

Also trades on Shenzhen Stock Exchange · 000028.SZ (CNY) Shenzhen Stock Exchange · 200028.SZ (HKD)
Description

China National Accord Medicines Corporation Ltd. primarily focuses on the wholesale and retail distribution of a wide array of pharmaceutical and medical products. The company's extensive product offerings include traditional Chinese remedies, advanced biochemical and biological medicines, diagnostic agents, and antibiotics. Additionally, it supplies various chemical preparations, food items, industrial chemicals, and a diverse range of other general commodities. Beyond its core sales activities, the company is involved in selling medical apparatus and instruments. It offers comprehensive logistics services, encompassing freight transportation, warehousing, and cargo handling, alongside professional consulting. Further diversifying its operations, it markets glassware, cosmetics, and daily necessities, and provides goods agency services. The firm also participates in the import and export of technology, leases properties, and engages in the wholesale and retail of health-related products. As of December 31, 2021, China National Accord Medicines managed a significant network of 8,798 drugstores across 20 provinces, autonomous regions, and municipalities within China. This expansive retail footprint included 7,257 directly owned stores and 1,541 franchised locations. Established in 2004 and based in Shenzhen, China, the company operates as a subsidiary of Sinopharm Group Co., Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY21.09 +0.32 (+1.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.15
Float Shares
168.78M
Free Float %
34.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.74% -1.17% -4.76% -8.56% -5.06% -3.83% -6.12% -48.32% -22.94% -50.96% +578.74%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
21.09
DCF (Unlevered) 216.95 +928.7%
DCF (Levered) 342.40 +1,523.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 60% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 2 0
Hold 0 -1
Sell 2 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.57
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Distribution: +5.6%
    -1.3% Q1'26: -2.6% (vs Q1'25)
  • ✓
    EPS growth Medical - Distribution: +4.9%
    +77.4% ★ Q1'26: -11.9% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Distribution: +37.6%
    +2.1% Q1'26: -16.6% (vs Q1'25)
  • ✗
    EBIT margin Medical - Distribution: +3.0%
    +2.3% Q1'26: +2.1% (vs Q1'25)
  • ✗
    ROIC Medical - Distribution: +5.7%
    +6.0% ★ Q1'26: +4.1% (vs Q1'25)
  • ✓
    Share dilution Medical - Distribution: +0.0%
    -0.3% ★ Q1'26: -0.6% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×
    4.79× Q1'26: 8.70× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.18) × ERP
WACC = 47% × Ke + 53% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 220.80 Current price: 21.09
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
2 EPS Ana. 		Dec 2027
5 Rev. Ana.
5 EPS Ana. 		Dec 2028
1 Rev. Ana.
2 EPS Ana.
Revenue
37.82B
est: 26.50B (+42.7%)
41.25B
est: 38.84B (+6.2%)
41.26B
est: 41.26B (0.0%)
43.12B
est: 42.97B (+0.3%)
52.79B
est: 49.63B (+6.4%)
59.65B
est: 58.42B (+2.1%)
68.36B
est: 68.77B (-0.6%)
73.44B
est: 73.88B (-0.6%)
75.48B
est: 75.68B (-0.3%)
74.38B
est: 75.57B (-1.6%)
73.42B
est: 75.26B (-2.4%)
75.58B
73.84B – 77.31B
+0.4% YoY
78.20B
73.55B – 83.57B
+3.5% YoY
80.12B
76.78B – 83.84B
+2.5% YoY
EBITDA
1.49B
est: 937.27M (+58.8%)
1.58B
est: 1.37B (+15.1%)
1.38B
est: 1.46B (-5.4%)
1.54B
est: 1.52B (+1.1%)
1.85B
est: 1.76B (+5.1%)
2.11B
est: 2.07B (+1.9%)
2.24B
est: 2.43B (-8.0%)
2.54B
est: 2.61B (-2.7%)
3.84B
est: 2.68B (+43.3%)
1.74B
est: 3.41B (-49.0%)
3.06B
est: 3.39B (-9.7%)
3.41B
3.33B – 3.48B
+0.4% YoY
3.52B
3.31B – 3.77B
+3.5% YoY
3.61B
3.46B – 3.78B
+2.5% YoY
EBIT
1.33B
est: 772.66M (+72.6%)
1.43B
est: 1.13B (+25.9%)
1.28B
est: 1.20B (+6.8%)
1.43B
est: 1.25B (+14.4%)
1.71B
est: 1.45B (+18.4%)
1.94B
est: 1.70B (+13.8%)
2.03B
est: 2.01B (+1.3%)
2.30B
est: 2.15B (+6.7%)
2.41B
est: 2.21B (+9.3%)
1.51B
est: 2.06B (-26.6%)
1.70B
est: 2.05B (-17.1%)
2.06B
2.02B – 2.11B
+0.4% YoY
2.14B
2.01B – 2.28B
+3.5% YoY
2.19B
2.10B – 2.29B
+2.5% YoY
Net Income
927.61M
est: 915.17M (+1.4%)
1.19B
est: 1.06B (+12.4%)
1.06B
est: 1.18B (-10.3%)
1.21B
est: 1.21B (+0.3%)
1.27B
est: 1.27B (-0.3%)
1.40B
est: 1.43B (-2.3%)
1.34B
est: 1.50B (-11.2%)
1.49B
est: 1.46B (+1.6%)
1.60B
est: 1.61B (-0.9%)
642.49M
est: 1.28B (-49.7%)
1.14B
est: 1.16B (-2.2%)
1.21B
1.18B – 1.24B
+4.0% YoY
1.28B
881.98M – 1.48B
+6.0% YoY
1.34B
1.27B – 1.42B
+4.9% YoY
SGA
2.39B
est: 2.17B (+10.2%)
2.46B
est: 3.17B (-22.7%)
2.39B
est: 3.37B (-29.1%)
2.83B
est: 3.51B (-19.5%)
3.87B
est: 4.06B (-4.6%)
4.74B
est: 4.78B (-0.7%)
5.49B
est: 5.62B (-2.3%)
6.08B
est: 6.04B (+0.7%)
6.20B
est: 6.19B (+0.2%)
6.24B
est: 5.27B (+18.4%)
1.43B
est: 5.25B (-72.7%)
5.27B
5.15B – 5.39B
+0.4% YoY
5.45B
5.13B – 5.83B
+3.5% YoY
5.59B
5.36B – 5.85B
+2.5% YoY
EPS
1.68
est: 1.64 (+2.6%)
2.15
est: 1.89 (+13.8%)
1.90
est: 2.11 (-10.0%)
2.18
est: 2.16 (+0.9%)
2.28
est: 2.28 (+0.2%)
2.52
est: 2.57 (-1.9%)
2.40
est: 2.69 (-10.9%)
2.67
est: 2.62 (+1.9%)
2.87
est: 2.89 (-0.6%)
1.15
est: 2.29 (-49.8%)
2.04
est: 2.09 (-2.2%)
2.17
2.11 – 2.23
+4.0% YoY
2.30
1.58 – 2.66
+6.0% YoY
2.41
2.28 – 2.56
+4.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-28 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-27 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-26 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-25 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-22 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-21 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-20 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-19 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-18 B+ 3/5 5/5 3/5 4/5 1/5 2/5 4/5
2026-05-15 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-05-14 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-05-13 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-05-12 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-05-11 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-05-08 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-05-07 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-05-06 A- 4/5 5/5 3/5 4/5 1/5 3/5 5/5
2026-04-30 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-29 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-28 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-27 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-24 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-23 C+ 2/5 5/5 1/5 1/5 1/5 3/5 1/5
2026-04-22 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-04-21 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-04-20 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-04-17 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5
2026-04-16 A- 4/5 5/5 3/5 4/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.43B
OE per share TTM
2.57
Owner's Yield
10.94%
Maintenance CapEx ratio
14.63%
Maint CapEx / Avg PPE
4.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 26 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 State Street SPDR S&P Emerging Markets Small Cap ETF EWX 0.02% 149.6K 0.65%
2 Franklin FTSE China UCITS ETF FLXC.L 0.01% 100.3K 0.19%
3 Dimensional - Emerging Markets Value ETF DFEV 0.00% 59.6K 0.46%
4 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 179.0K 0.39%
5 Vanguard FTSE All-World High Dividend Yield UCITS ETF VHYD.L 0.00% 161.2K 0.29%
6 Vanguard FTSE All-World High Dividend Yield UCITS ETF (USD) Accumulating VHYA.L 0.00% 161.2K 0.29%
7 Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L 0.00% 71.1K 0.17%
8 Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L 0.00% 71.1K 0.17%
9 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 12.9K 0.48%
10 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 29.2K 0.26%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
43.2K
Shares Outstanding
485.21M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Baochun Lang General Counsel, Chief Legal Counsel & Chairman of the Trade Union — male
Changbing Chen Deputy General Manager — male
Chuan Li Deputy GM & Board Secretary — male
Guolin Gu Deputy GM, CFO, General Counsel & Chief Compliance Officer — male
Jinxiong Li GM & Non-Independent Director — male
Xuefei Wang Accounting Supervisor — —
Zhaoxiong Lin GM & Non-Independent Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Distribution